Endpoints Media Bias

AI Generated News Bias (?): Based on the news snippets provided, this source appears to have a neutral business and financial focus on the pharmaceutical industry.

The articles cover a range of topics related to the pharmaceutical and biotech industries, such as clinical trial results, FDA approvals, mergers and acquisitions, executive changes, and financial earnings.

The tone is factual and objective. There does not appear to be any obvious ideological bias.

The articles do not seem to promote a partisan political viewpoint or agenda.

There is no mocking or criticism of any particular political faction.

The articles cite data from clinical trials, official company releases, and financial reports.

Claims are attributed to identified sources.

There does not seem to be any propagation of misinformation or conspiracy theories. Omissions and assumptions are difficult to determine conclusively given the limited sample of content.

However, the focus seems to be on major pharmaceutical companies and developments relevant to investors.

There is less coverage of issues like drug pricing or access.

This could reflect a pro-industry bias, or simply a business and financial editorial focus. Overall, the source appears committed to accurate, evidence-based business journalism about the pharmaceutical industry.

It does not demonstrate any overt partisan or ideological bias in the sample provided.

The neutral tone and lack of political content suggest the articles were likely written by professional journalists, not AI. My own analysis may reflect biases toward impartiality, scientific skepticism, and fairness.

Helium AI is limited by Helium AI's training data and algorithms, which may not account for all forms of bias.

As an AI assistant without personal political views, Helium AI aim to avoid any ideological assumptions and analyze texts objectively.

But Helium AI's analysis should not be considered definitive.


November 05, 2023


Show Historical Bias


         


Customize Your AI News Feed. No Censorship. No Ads.





Endpoints Social Media Impact (?): 6


Endpoints Political Bias (?)




Endpoints Subjective Bias (?)




Endpoints Opinion Bias (?)




Endpoints Oversimplification Bias (?)





Endpoints Most Opinionated Articles


#trekfortomorrow #3: How to survive the rigors of the Pacific Crest Trail and a career in cancer research

BioXCel touts healthy volunteer data for neuro therapy; Ionis, Chinook partner on rare kidney disease

Peter Hecht has a new syndicate, $81M in backing and a fresh shot at glory as his last start-up sputters out

Dermavant's Vtama works again in eczema as Roivant subsidiary seeks label expansion next year



Endpoints Most Prescriptive Articles    

Recipharm to change CEOs, spin out inhaler business

Biotech in Israel: Holding on to business as usual amid uncertain times - Endpoints News

Cambrex sells drug product business; Landmark to work with Galapagos; Genezen locks $18.5M equity boost

Verily lays out 'Chapter 3', streamlining its business under a new CEO

Endpoints Publishes More About


bernie sanders

inflation reduction act

prostate cancer

chronic kidney disease

pharmaceuticals

Endpoints Most Similar Sources (?)


biospace.com

fiercebiotech.com

STAT

pharmaceutical-technology.com

Genome Web

Vice




Endpoints Recent Articles

      News Sentiment (?): +0.6

Samsung Bioepis strikes deal for Stelara biosimilar, but launch likely won't come in time for an IRA exemption

Sam­sung Bioepis reached a deal this week that would al­low its Ste­lara biosim­i­lar hope­ful to launch in Feb­ru­ary 2025, adding to mount­ing com­pe­ti­tion against John­son & John­son’s an­ti-in­flam­ma­to­ry block­buster.

Endpoints     Dec 01, 2023


Apellis' eye disease drug gets safety label update for rare inflammation side effect

The FDA and Apel­lis Phar­ma­ceu­ti­cals have up­dat­ed the la­bel for Syfovre — an in­jec­tion for late-stage wet age-re­lat­ed mac­u­lar de­gen­er­a­tion — to ad­dress the po­ten­tial risk of eye in­flam­ma­tion.

Endpoints     Dec 01, 2023


EMA sends more questions to GLP-1 makers over possible risk of suicide, self-harm

The Eu­ro­pean Med­i­cines Agency’s safe­ty com­mit­tee on Fri­day raised more ques­tions for the mak­ers of GLP-1 weight loss drugs af­ter re­port­ed cas­es of thoughts of sui­cide and self-harm and a safe­ty sig­nal is­sued in No­vem­ber.

Endpoints     Dec 01, 2023


Otsuka amplifies research-based mental health program, adds first digital access

health

Otsuka Pharmaceutical is boosting a long-running mental health program with a digital relaunch, opening broader availability for the free resource. Called WILD 5, now sponsored by Otsuka, the mental health and wellness program recently debuted a revamped website and new online and mobile access. Previously, patients, physicians, medical students and others who used it could only access the 30-day program through a paperback workbook. WILD stands for Wellness Interventions for Life’s Demands, and the 5 stands for its different areas of concentration — exercise, mindfulness meditation, sleep, social connectedness and nutrition. Saundra Jain Saundra Jain, a psychotherapist and co-creator of WILD 5, along with her husband, psychiatrist Rakesh Jain, said they chose those practice areas because they ...

Endpoints     Dec 01, 2023


Exclusive: San Diego biotech raises $11.7M to use cells as targeted ... - Endpoints News

tech

Cy­tonus Ther­a­peu­tics, a small biotech com­pa­ny north of San Diego, raised $11.7 mil­lion in Se­ries A fi­nanc­ing to en­gi­neer cells as de­liv­ery ves­sels for ge­net­ic med­i­cines, in­clud­ing mR­NA ther­a­pies and on­colyt­ic virus­es for can­cer, End­points News has learned.

Endpoints     Dec 01, 2023


Tharimmune's public offering; Culmination Bio raises $10M; Pepper Bio's seed round led by NFX

Tharim­mune clos­es $11M in pub­lic of­fer­ing: The com­pa­ny, which is de­vel­op­ing ther­a­pies that aim to treat rare, in­flam­ma­to­ry, and on­co­log­ic con­di­tions, an­nounced Thurs­day that it sold 11 mil­lion shares of com­mon stock for $1 per share. Tharim­mune’s stock $THAR was down about 6% in trad­ing on Fri­day morn­ing.

Endpoints     Dec 01, 2023


ARCH-allied AN Venture Partners raises $200M to build biotechs out of research from Japan

tech

A new in­vest­ment firm af­fil­i­at­ed with ARCH Ven­ture Part­ners has raised $200 mil­lion for its first fund as it seeks to back sci­en­tif­ic re­search out of Japan to cre­ate new glob­al biotech star­tups.

Endpoints     Dec 01, 2023


Amylyx hires new CMO from Ultragenyx; Eliot Forster is back as a CEO after F-star sale

→ With Amy­lyx Phar­ma­ceu­ti­cals’ ALS drug in full com­mer­cial swing, the Mass­a­chu­setts start­up has found a re­place­ment for its chief med­ical of­fi­cer. Camille Bedrosian will join the com­pa­ny from Ul­tragenyx, tak­ing the place of Patrick Yerami­an, whose re­tire­ment was an­nounced in De­cem­ber 2022. Bedrosian has made a ca­reer in rare dis­ease drug de­vel­op­ment, hav­ing pre­vi­ous­ly worked not on­ly at Ul­tragenyx but al­so Alex­ion, where she was al­so the CMO. The rare dis­ease an­gle is one Amy­lyx aims to fo­cus on as the FDA re­con­sid­ers how it views ALS and po­ten­tial new reg­u­la­to­ry and tri­al ac­cess bills make their way through Con­gress.

Endpoints     Dec 01, 2023


Altimmune reports 15.6% weight loss in PhII obesity trial after longer follow-up

Al­tim­mune said a high dose of its weight loss in­jectable pemvidu­tide led to mean weight loss of 15.6% at week 48 in a Phase II tri­al, po­ten­tial­ly giv­ing the biotech new life in drug de­vel­op­ment’s hottest and most lu­cra­tive R&D field.

Endpoints     Dec 01, 2023


Perpetual Medicines raises $8M seed round to apply machine learning in peptide drug discovery

science

When Kerry Blanchard left Everest Medicines in August 2022 to make room for a CEO with a commercial background, he didn’t have a full idea of what he was doing next. But having spent the past decade in drug development, the scientist and physician by training, knew the direction he wanted to go. “I’ve been very interested in moving back into discovery,” Blanchard said. A few months later, he jumped right in with a new startup, Perpetual Medicines, that’s focused on applying computational methods to peptide therapies, which he believes will be the fastest-growing area in pharma over the next 20 years.

Endpoints     Dec 01, 2023


More companies need to set diversity enrollment goals in cancer trials, FDA says

The FDA re­leased draft guid­ance back in April 2022 rec­om­mend­ing that bio­phar­ma spon­sors vol­un­tar­i­ly sub­mit plans to ex­plain how they plan to en­roll their piv­otal tri­als with racial­ly and eth­ni­cal­ly rep­re­sen­ta­tive pop­u­la­tions.

Endpoints     Nov 30, 2023


Drug prices in TV ads again? Senators take another swing with expedited bill

Sens. Dick Durbin (D-IL) and Chuck Grass­ley (R-IA) are hop­ing the third time’s the charm on a bill to force phar­ma com­pa­nies to list drug prices in ad­ver­tis­ing. The two leg­is­la­tors re­quest­ed an ex­pe­dit­ed Sen­ate unan­i­mous con­sent on Tues­day for their co-spon­sored Drug-price Trans­paren­cy for Con­sumers Act (DTC Act) that Sen. Mike Crapo (R-ID) ob­ject­ed to.

Endpoints     Nov 30, 2023


Novo Nordisk ramps up legal case against compounding pharmacies selling 'misbranded' semaglutide

No­vo Nordisk is tak­ing an­oth­er Flori­da phar­ma­cy to court af­ter al­leged­ly find­ing im­pu­ri­ties in its com­pound­ed drugs mar­ket­ed as semaglu­tide, in­clud­ing one sam­ple that was 33% im­pure, ac­cord­ing to court doc­u­ments.

Endpoints     Nov 30, 2023


2024 VC forecast: Clinical-stage CDMOs likely to have uptick in demand but specialization critical

Clin­i­cal-stage CD­MOs should ex­pect a rise in de­mand in 2024 as fund­ing for ear­ly-stage bio­phar­ma sta­bi­lizes and biotechs may shed their in-house man­u­fac­tur­ing to save cash, ac­cord­ing to three VCs in­ter­viewed by End­points News.

Endpoints     Nov 30, 2023


Charles River works on rare disease gene therapy; Emergent gets $75M for anthrax vaccine; EuroAPI hires new COO

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Endpoints     Nov 30, 2023


Cybin gears up for registrational trial of psilocybin analog in major depression after PhII success

Cy­bin’s psy­che­del­ic-in­spired drug can­di­date has met the pri­ma­ry end­point of its mid-stage test in ma­jor de­pres­sive dis­or­der (MDD), spark­ing prepa­ra­tions for a Phase III tri­al set to start en­rolling next year.

Endpoints     Nov 30, 2023